Prev post
USD $10m Sale to Cardinal Health
Biovend develops web enabled secure vending freezers to dispense biological reagents in medical research laboratories
Biovend develops web enabled secure vending freezers to dispense biological reagents in medical research laboratories
Posted

In 2001 on behalf of venture capital investor Momentum Ventures, Jason Bresnehan was appointed the interim CEO of Biovend after the departure of the founding CEO. Biovend develops web enabled secure vending freezers to dispense biological reagents in medical research laboratories.
In June 2003 , after recruiting new operational and engineering management, getting the R&D program on track, concluding a trial sale with one of the world's leading life science biological reagents manufacturers Invitrogen Corporation, and negotiating a Series B venture capital round , Jason put together an extensive strategic marketing plan for the Company's entry into the global life sciences sector.
The international marketing plan also included strategies and tactics to penetrate smaller market segments including Surgical, Pharmaceutical Manufacture, Secure & Traceable Products (e.g. frozen stored adhesives in the aerospace sector).
About Biovend
Are you a Tasmanian business looking for a professional to help you manage an M&A transaction. Contact Evahan Managing Director and Principal Consultant Jason Bresnahan to explore how he can assist.
15 December 2025
Evahan Group is pleased to announce that Jason Bresnehan has been appointed as a Council Member on the Finance Council…
11 December 2025
Today marks the release of A Catholic Gospel Journey – Through the Lens of Alcohol Recovery, published under Bresnehan…
09 December 2025
Bresnehan Family Office investee, Hadspen Foundation awarded St Vincent Pallotti Scholarship for Lay Ministry for a…